TD Cowen initiated coverage of Oruka Therapeutics with a Buy rating and no price target. Oruka is backed by “sophisticated” monoclonal antibody engineering and both ORKA-001 and ORKA-002 have a high probability of success by targeting the same epitope as Skyrizi/Bimzelx, the analyst tells investors in a research note. The firm says the Oruka story “satisfies investor hunger for accessible yet protected biologics targeting large, established markets.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments
- Oruka initiated with a Buy at Jefferies
- Oruka announces $200M private placement
- Oruka Therapeutics Announces $200 Million Private Placement
- Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue